Me Therapeutics Holdings, Inc. · CSE:METX
Me Therapeutics — Investor Presentation (December 2023)
25 slides from Me Therapeutics's investor presentation, December 2023
Slide 1: We target suppressive myeloid cells to treat cancer
We target suppressive myeloid cells to treat cancer
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT The information contained in this presentation is provided for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy securities. Sale of securities, if any, will be restricted to those persons to whom the securities may
Slide 3: Introduction
INTRODUCTION Immuno oncology (IO) is a new area of cancer research which has been immensely successful in treating previously untreatable cancers. IO targets the immune system rather than the cancer directly which allows a single IO drug to be used to treat multiple cancer types with mostly manageab
Slide 4: Facts on cancer
Facts on cancer 2018 > 18.1 million new cases of cancer > 9.5 million deaths worldwide 2021 > $26 billion > Global IO market* 2030 > $154 billion > expected growth of global IO market* By 2040 > 29.5 million new cancer cases > 16.4 million deaths * Spherical Insights (cancer.gov) Me Therapeutics | I
Slide 5: The Landscape
The Landscape Our drugs target the immune system and not the cancer directly so they can be used in many different cancer types. Breast cancer Pricing and target market (297,790 estimated cases in the U.S. in 2023)* Current IO drugs (Keytruda, Opdivo) = $150,000 per patient irrespective of cancer ty
Slide 6: We are leaders in the cancer research space
We are leaders in the cancer RESEARCH space with a proven track record of success Me Therapeutics | Investor Deck | 2023 6
Slide 7: Our Team
OUR TEAM Salim Dhanji | PhD, CEO and founder John Priatel | PhD, director and founder • Former director of preclinical research • Honorary Assistant Professor at University at Qu Biologics of British Columbia • Industry and academic expertise in cancer, • Expertise in lymphocyte biology, autoimmunit
Slide 8: Company Milestones: Where We Started
COMPANY MILESTONES WHERE WE STARTED 1 3 5 7 2017 2018 2016 Antibody Cell line pool for lead 2014 First stage of antibody humanization humanized antibody Founding humanization program complete production developed 2015 2016 2017 Discovered and tested First small molecule Second small high affinity an
Slide 9: Company Milestones: Where We're Headed
COMPANY MILESTONES WHERE WE’RE HEADED 1 3 5 7 2019 Accepted as 2015-2021 2023 2018 lone Canadian In-house R&D in Second myeloid PCT application company in vitro assays, in targeting prodrug filed on lead MIT IDEA2 vivo mouse developed (D099) antibodies incubator tumor models 2019 2015-2020 2022 Rece
Slide 10: Highlights
HIGHLIGHTS Strategy Safety Validate drug targets in widely Safety and efficacy data accepted animal models on lead antibody drug Target proof Proof of concept data Strong animal data for on new small molecule potential buyout drug formulations Me Therapeutics | Investor Deck | 2023 10
Slide 11: Technology
TECHNOLOGY We have the potential to use new technology to develop next generation drugs against our targets. OUR LEAD DRUG OUR PROGRAM Targeting key pathways in Anibody-based therapy myeloid cell biology OUR DISCOVERY STAGE DRUGS Small molecules into targeted lipid nanoparticle prodrugs Me Therapeut
Slide 12: Our Advantage
OUR ADVANTAGE Anti-G-CSF antibody (h1B11-12) advantages: • Late preclinical stage • Target = G-CSF: • High G-CSF → immune suppression, decreased survival, increased metastases, increased resistance to target therapy Myeloid targeting prodrugs (D094 and D099): • Preclinical stage • Block T cell suppr
Slide 13: Our Intellectual Property
OUR INTELLECTUAL PROPERTY PCT filed February 2018 on composition and use of lead anti-G- CSF antibodies (PCT/CA2018/050143) • Chinese patent granted in 2023 Patents on prodrugs will be filed once testing is complete • Initial search suggests freedom to operate based on proposed drug structures • Wil
Slide 14: Our Project Objectives
Our PROJECT OBJECTIVES Derisking G-CSF Prodrug targeting antibody program suppressive myeloid cells • Non-GMP drug manufacture (2 • Formulation of 2 prodrugs with partner months) (complete) • Preliminary safety study in non-human • Efficacy studies in accepted mouse cancer primate model (4-10 months
Slide 15: The Competition
THE COMPETITION BUYERS CSL We have a clear Buyout or Main competition advantage. ME partnerships for our G-CSF differs from our targeting drug peers as we have differentiated drug targets backed by strong science Small public biotechnology LARGE PHARMA • Carisma Therapeutics • Merck • Bristol • CERo
Slide 16: The Facts
The Facts IMPROVING THE EFFICANCY OF CURRENT IO Combination Therapies Can Improve Patient Outcome • Current IO drugs (especially checkpoint inhibitors) have shown remarkable efficacy in some patients • Most cancer types amenable to IO • I0 targets the immune system and not cancer directly • Not all
Slide 17: Myeloid cells hinder cancer killing
The facts MYELOID CELLS HINDER CANCER KILLING Myeloid Cells are a roadblock to immune checkpoints T cells • Checkpoint inhibitors focus on activating cancer killing T cells (Keytruda, Opdivo, Yervoy) Myeloid cells • Myeloid cells interfere with T cell function but can be targeted or reprogrammed to
Slide 18: Resources Required (12 Months)
RESOURCES REQUIRED (12MONTHS) OBTAIN A LISTING OF COMMON SHARES ON THE CSE - $80,000 G-CSF program Novel Lipid Nanoparticle Formulations • G-CSF antibody candidate non-GMP • For the Preferential Targeting of Suppressive manufacturing - $10,000 Myeloid Cells • Efficacy study at CRO - $50,000 • LNP Sc
Slide 19: The Major Players
The MAJOR PLAYERS Myeloid targeted drugs have great potential to improve the efficacy of checkpoint inhibitors with multi-billion dollar opportunity. Name: Keytruda (anti-PD-1) Name: Opdivo Sales: $20.9 billion in 2022 Sales: $8.25 billion in 2022 FACT: Every large pharmaceutical company has a drug
Slide 20: Major Players IO + TBD
MAJOR PLAYERS io + tbd Recent focus in combination therapies has shifted to myeloid cells to boost the efficacy of checkpoint inhibitors like Keytruda and Opdivo. Definition: Combined drugs Case in Point: Opdivo Targeting multiple pathways to ~$150,000 per patient (regular) improve effectiveness ~$2
Slide 21: Pipeline
Pipeline MOLECULE DISCOVERY PRECLINICAL PHASE 1 h1B11-12 (G-CSF Ab) D094 (myeloid prodrug) D099 (myeloid prodrug) Myeloid targeting LNPs Me Therapeutics | Investor Deck | 2023 21
Slide 22: Comparable Public Company Valuations
COMPARABLE PUBLIC COMPANY VALUATIONS Carisma Therapeutics CERo Therapeutics ~$300 million market cap ~$140 million market cap FortySeven Inc. Flexus Biosciences Bought by Gilead in 2020 Bought by Bristol-Myers for $4.9 billion Squibb for $1.2 billion in 2015 Me Therapeutics | Investor Deck | 2023 22
Slide 23: Summary & Exit Strategy
Summary & Exit Strategy 2023 2023 Safety and efficacy data on lead Proof of concept data antibody drug on new small molecule drug formulations Strategy Partners EXIT Use strong scientific expertise large pharma for human trials Pharma partnership to advance our novel IO drugs or buyout Me Therapeuti
Slide 24: ME Financials
ME FINANCIALS ME Therapeutics Inc. Statements of Loss and Deficit (Unaudited – see Notice to Reader) Year ended August 31 2020 2019 Revenue IRAP funding $ 34,120 $ 167,540 SR&ED funding 18,912 81,551 53,032 249,091 Expenses Salaries and wages 51,644 219,215 Research and development 13,282 98,856 Pro
Slide 25: Thank You
Salim Dhanji PhD CEO and founder Address 177 Robson St. Vancouver, BC, Canada V6B0N3 Contact Info Email: salim@metherapeutics.com Thank You
Me Therapeutics Holdings — Investor Presentation (December 2023) on 6ix